INTERTEK GROUP PLC (ITRK) — Investment Research Note

Executive summary

Intertek is a leading global Total Quality Assurance ("ATIC" – Assurance, Testing, Inspection, Certification) provider operating 1,000+ labs across 100+ countries, with FY25 revenue of £3,432m, 18.1% adjusted margin and 21.3% ROIC. Over the period 2023–H1 26 the company has executed strongly on its AAA strategy, delivering 6% average revenue growth, 240bps of margin accretion to 17.5%, consistent double-digit EPS growth and 110%+ cash conversion 2026-03-03 FY25, 2026-07-31 H1 26. The single most important fact for valuation today is that on 18 June 2026 the Board recommended a final cash offer of £61.077 per share from EQT/Luxinva/Mubadala (Isotope Bidco), with the Scheme Document issued on 15 July 2026 and completion expected Q4 2026/Q1 2027 — making this a near-deal-arb situation 2026-09-17 Offer Update, 2026-07-31 H1 26.

Fair value estimate

Fair value: 6,077–6,108p per share (implied mkt cap £9,328–£9,375m). Methodology: recommended final cash offer of 6,107.7p (inclusive of 107.7p FY25 final dividend already paid in the ordinary course) is the authoritative anchor; I also sense-checked against standalone fundamentals (FY25 adj. diluted EPS 253.5p × ~24x forward P/E, consistent with historical premium industrials/TIC multiples, gives ~6,100p). The offer is final under Rule 2.7, so no bump absent a competing bid.

• Latest disclosed market cap: £9,025.6m; current price 5,890p
• Fair value mid implied market cap: ~£9,350m
• Absolute upside: ~+3.7% to deal consummation; cap-and-collar return with Q4 26/Q1 27 timing (~3 months)

Key assumption: scheme completes on current terms. If deal breaks, standalone fair value likely 4,800–5,400p (where the stock traded before offer speculation per the price history: 3,648p in March 2026 after the strategic-review announcement).

Sector context

• Sector classification confirmed: Industrials / Industrial Goods and Services (Professional Services / TIC).
• Intertek's quality, growth, margin and ROIC profile is above typical industrial peers — 18.1% adj. margin and 21% ROIC are top-decile versus industrial averages. Balance sheet (1.4x net debt/EBITDA) is in line with sector.
• Listed peers: Bureau Veritas (BVI.PA), SGS (SGSN.SW), Eurofins Scientific (ERF.PA), ALS Limited (ALQ.AX).

Investment thesis (at current price)

1. De-risked cash takeout at 6,107.7p. EQT-led consortium offer is recommended by the Board, binding under Rule 2.7, with Interim Facilities of £4,430m already in place and lender presentation issued 17 September 2026 — financing risk is low 2026-09-17 Offer Update, 2026-07-31 H1 26.
2. Strong operational momentum into completion. H1 26 delivered 6.1% constant-currency revenue growth, 100bps margin accretion to 17.5%, 12.4% EPS growth and 116% cash conversion — reduces risk of material adverse change and supports deliverability 2026-07-31 H1 26.
3. Quality underlying franchise provides floor if deal breaks. Scale leadership across 5 divisions, 400,000 clients, 70%+ recurring revenue, consistent 21%+ ROIC through cycles — standalone intrinsic value likely in the 4,800–5,400p range would limit downside in a break scenario 2026-03-03 FY25.

Key risks

1. Regulatory/antitrust block or shareholder rejection. Completion is subject to regulatory approvals and shareholder vote (held 6 August 2026); any delay or failure would see the stock reset to pre-offer levels (~4,700p area) 2026-07-31 H1 26.
2. Capped upside / minimal operating-leverage benefit for the strategy buyer. Since the offer is final and no counter-bidder has emerged after 3+ months, the holder captures ~3.7% to completion and is then forced out for cash — no long-tail participation in post-deal value creation 2026-09-17 Offer Update.
3. China/Middle East operational exposure to geopolitical shocks. Caleb Brett and Government & Trade Services exposed to Middle East disruption; H1 26 World of Energy op profit fell 16.3% on these issues (not disclosed as a deal-break risk but inferred as potential MAC trigger).

Operating leverage

Intertek has a genuinely operationally-leveraged ATIC model: with ~£1.5bn employee costs on £3.4bn revenue, significant fixed-site/laboratory overhead and ~22% of revenue in high-margin Assurance (29% CP margin, 23% Corporate Assurance), incremental revenue drops disproportionately. The group's own disclosure quantifies this: H1 26 revenue +6.1% translated into adj. operating profit +12.4% (operating leverage of ~2x) and adj. EPS +12.4%. The Consumer Products division operates at 29.4% adj. margin (+120bps on 5.3% LFL growth) and is explicitly cited as benefiting from "operating leverage and productivity gains" 2026-07-31 H1 26, 2026-03-03 FY25. However, this is bounded operating leverage — not SaaS-grade — and the margin trajectory is explicitly managed toward an 18.5%+ medium-term target rather than runaway convexity. A hypothetical 10–20% revenue beat would plausibly deliver roughly 50% incremental operating profit uplift, consistent with the mid-60s score range.

Value-trap signals

None identified. Growth is accelerating, margins expanding, cash flow strong, no visible accounting red flags, dividend record intact (105.8p FY22 → 165p FY25), unqualified Deloitte opinion, no going-concern issues flagged.

Earnings vs. expectations

Across the 11 consecutive six-month periods disclosed (H1 21 → H1 26), Intertek has delivered mid-single digit LFL revenue growth and 7 consecutive six-month periods of double-digit adjusted EPS growth, consistently meeting or beating management's stated guidance of "mid-single digit LFL revenue growth, margin progression, strong cash flow." The 2025 FY beat (adj. EPS +10.1% CCY) and H1 26 beat (adj. EPS +12.4% CCY) saw guidance reiterated or upgraded. Pattern: consistent in-line to modest beats; no profit warnings in the window reviewed 2026-07-31 H1 26, 2026-03-03 FY25, 2025-08-01 H1 25. Analyst consensus not explicitly cited in the filings.

Conviction

Conviction: 5 (very high) — on the fair-value call, not on the stock's attractiveness.

Anchors: (i) Recommended final cash offer at a specific price is a binding valuation anchor far superior to DCF/multiple estimates; (ii) Scheme Document, lender presentation and interim facilities all in place, with Board recommendation unanimous; (iii) Clean, Deloitte-audited financials with no accounting issues.

Limiters: (i) Residual regulatory/antitrust completion risk could still break the deal (small but non-zero); (ii) If break occurs, standalone fair value is a wider range given the 2026 strategic-review optionality.

Driver scoring summary

Overall score: 220 / 1000 — Low fit for this investor's strategy.

The stock is 3 months from being taken private at a fixed cash price. The investor's whole thesis — AI-receiver exposure, operating leverage, long-tail upside at a fair price with downside protection — is structurally incompatible with a near-term cash takeout: the holder gets ~3.7% to completion and is then forced out for cash with zero further participation. The underlying business is high-quality (which rescues the score from the bottom band), but Intertek offers no AI-driven operating-leverage long tail from here. If the investor wants pure deal-arb spread, this works; if they want strategy-fit, it does not.